Ranibizumab - Biologic Drug Details

Summary for ranibizumab

Tradenames:	2
High Confidence Patents:	9
Applicants:	3
BLAs:	4
Suppliers: see list	5
Recent Clinical Trials:	See clinical trials for ranibizumab
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ranibizumab

Recent Clinical Trials for ranibizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Tasly Pharmaceutical Group Co., Ltd	PHASE3
Hoffmann-La Roche	PHASE3
Genentech, Inc.	PHASE3

See all ranibizumab clinical trials

Recent Litigation for ranibizumab

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
GENENTECH, INC. v. DR. REDDYS LABORATORIES, INC.	2023-11-17
Genentech, Inc. v. Biogen MA Inc.	2023-07-13
Genentech, Inc. v. Centus Biotherapeutics Limited	2020-11-12

See all ranibizumab litigation

Pharmacology for ranibizumab

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ranibizumab Derived from Brand-Side Litigation

These patents were obtained from brand-side disclosures in response to biosimilar applications

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Patent Expiration
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	June 30, 2006		2034-03-14
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	March 20, 2018		2034-03-10
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	August 10, 2012		2028-07-08

2) High Certainty: US Patents for ranibizumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156		2038-10-04	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156		2021-11-01	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156		2022-09-12	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ranibizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156		2037-12-21	Patent claims search
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156		2036-12-20	Patent claims search
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156		2037-07-18	Patent claims search

International Patents for ranibizumab

Country	Patent Number	Estimated Expiration
Taiwan	I702225
European Patent Office	3685826
Japan	2007511737

Ranibizumab Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for Ranibizumab?

Ranibizumab, marketed under the brand name Lucentis, is a monoclonal antibody fragment approved for treating wet age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and myopic choroidal neovascularization. Its market size and competitive landscape are shaped by factors including disease prevalence, regulatory approvals, and the competitive profile of alternative therapies.

Market Size and Growth

The global market for ranibizumab was valued at approximately USD 4 billion in 2022 and projected to reach USD 6 billion by 2028, growing at a compound annual growth rate (CAGR) of roughly 7 percent. Drivers include aging populations, increasing prevalence of diabetes and retinal diseases, and expanding off-label uses.

Key Market Drivers

• Aging Population: The global population aged over 60 is expected to reach 1.4 billion by 2030, up from 1 billion in 2020. Age-related macular degeneration (AMD) prevalence correlates directly with age, increasing demand for ranibizumab.

• Diabetes Epidemic: The International Diabetes Federation reports over 537 million adults living with diabetes in 2021. Diabetic retinopathy, leading to DME, is a common complication necessitating anti-VEGF therapies like ranibizumab.

• Regulatory Expansion: Approved for use in more indications globally, including some forms of retinal vein occlusion, with ongoing studies for myopic choroidal neovascularization.

Competitive Landscape

Ranibizumab faces competition primarily from:

• Aflibercept (Eylea): Often priced lower, with similar efficacy in many indications. It has advantages in dosing intervals, reducing treatment burden.
• Bevacizumab (Avastin): Off-label use, significantly lower cost, but lacks formal regulatory approval for ophthalmic indications in many markets.
• Emerging Biosimilars: Several biosimilars are under development, targeting cost reduction and expanding access.
• Emerging Therapies: Small molecule inhibitors and gene therapies are progressing, potentially disrupting the anti-VEGF space.

Pricing and Reimbursement

World-wide, retail prices for ranibizumab average USD 2,000-2,500 per injection. Reimbursement policies vary but often limit repeated injections or impose risk-sharing agreements with payers, influencing market penetration and pricing strategies.

What Is the Financial Trajectory for Ranibizumab?

Revenue Trends

Ranibizumab's revenue peaked around USD 4.2 billion in 2020. Since then, revenues have modestly declined due to increased competition and biosimilar entries, especially in Europe and emerging markets.

Cost Structure

Research and development costs for anti-VEGF agents typically range from USD 200 million to USD 500 million per development cycle. Manufacturing costs are relatively low per dose but are offset by significant marketing and distribution expenses.

Profitability Outlook

Profit margins for established biologics like ranibizumab typically range from 30 to 60 percent, depending on scale and market access. Patent expirations and biosimilar competition forecast potential erosion of margins over the next five years.

Regulatory and Patent Environment

Lucentis's primary patents expired in the U.S. and EU in 2022-2023, opening the door for biosimilar competition. Ensuring market share involves implementing risk-sharing agreements, expanding indications, and optimizing dosing frequency.

Future Revenue Opportunities

• Expanded Indications: Ongoing trials for new uses could augment revenues.
• Pricing Strategies: Use of biosimilar competition to drive innovation in dosing or formulation.
• Off-Label Uses: Growth in off-label administration could provide additional revenue streams.

What Are the Risks to Market and Financial Trajectory?

• Patent Cliffs: Patent expiration invites biosimilar entries that typically reduce prices by 20-40 percent.
• Competitive Therapies: Development of gene therapies and oral agents may challenge injectable biologics.
• Market Penetration: Reimbursement limits and treatment frequency compliance affect market share.
• Regulatory Changes: Approval processes and pricing policies vary across markets and can impact revenue.

Key Takeaways

Ranibizumab remains a leading anti-VEGF therapy for retinal diseases, supported by aging demographics and increasing disease prevalence. Market growth is steady but faces pressure from biosimilars and alternative treatments. Revenues peaked recently and are expected to decline with patent expirations and biosimilar entry, though expansion into new indications and strategies to maintain market share could offset some losses. Competitive pricing and market access policies are vital for sustaining profitability.

FAQs

1. What is the primary competitor to ranibizumab?

   • Aflibercept (Eylea) is the main competitor, offering similar efficacy with fewer injections.

2. How has patent expiration affected ranibizumab revenues?

   • Patent expiry in 2022-2023 has opened biosimilar markets, leading to price reductions and revenue pressure.

3. Are biosimilars globally available for ranibizumab?

   • Biosimilar development is ongoing, with approvals in several regions, including Europe and Asia.

4. What are potential new indications for ranibizumab?

   • Research is ongoing for indications like myopic choroidal neovascularization and diabetic retinopathy.

5. How do pricing and reimbursement strategies impact market share?

   • High prices and reimbursement restrictions limit access, while risk-sharing agreements and broader indications can improve uptake.

---

References

1. MarketWatch. "Global Ranibizumab Market Size to Reach USD 6 billion by 2028," 2022.
2. International Diabetes Federation. Diabetes Atlas, 10th Edition, 2021.
3. FDA. "Lucentis (ranibizumab) for intravitreal injection," 2022.
4. Merck. "Biosimilar Development and Market Entry," 2023.
5. IQVIA. "Global Ophthalmology Drugs Market Report," 2022.